About: A low molecular weight, selective thrombin inhibitor, inogatran, vs heparin, in unstable coronary artery disease in 1209 patients. A double-blind, randomized, dose-finding study. Thrombin inhibition in Myocardial Ischaemia (TRIM) study group

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: A low molecular weight, selective thrombin inhibitor, inogatran, vs heparin, in unstable coronary artery disease in 1209 patients. A double-blind, randomized, dose-finding study. Thrombin inhibition in Myocardial Ischaemia (TRIM) study group Goto Sponge NotDistinct Permalink

An Entity of Type : wikibase:Item, within Data Space : wikidata.demo.openlinksw.com associated with source document(s)

scientific article published on 01 September 1997

Attributes	Values
rdf:type	Item
description	wetenschappelijk artikel (nl) наукова стаття, опублікована у вересні 1997 (uk) article scientifique publié en 1997 (fr) im September 1997 veröffentlichter wissenschaftlicher Artikel (de) artículu científicu espublizáu en setiembre de 1997 (ast) scientific article published on 01 September 1997 (en)
publication date	wds:Q74152408-81544E7B-136D-47C6-ABE8-8BA419732DC1
publication date	1997-09-01 00:00:00Z (xsd:dateTime)
rdfs:label	A low molecular weight, selective thrombin inhibitor, inogatran, vs heparin, in unstable coronary artery disease in 1209 patients. A double-blind, randomized, dose-finding study. Thrombin inhibition in Myocardial Ischaemia (TRIM) study group (en) A low molecular weight, selective thrombin inhibitor, inogatran, vs heparin, in unstable coronary artery disease in 1209 patients. A double-blind, randomized, dose-finding study. Thrombin inhibition in Myocardial Ischaemia (TRIM) study group (nl)
skos:prefLabel	A low molecular weight, selective thrombin inhibitor, inogatran, vs heparin, in unstable coronary artery disease in 1209 patients. A double-blind, randomized, dose-finding study. Thrombin inhibition in Myocardial Ischaemia (TRIM) study group (en) A low molecular weight, selective thrombin inhibitor, inogatran, vs heparin, in unstable coronary artery disease in 1209 patients. A double-blind, randomized, dose-finding study. Thrombin inhibition in Myocardial Ischaemia (TRIM) study group (nl)
name	A low molecular weight, selective thrombin inhibitor, inogatran, vs heparin, in unstable coronary artery disease in 1209 patients. A double-blind, randomized, dose-finding study. Thrombin inhibition in Myocardial Ischaemia (TRIM) study group (en) A low molecular weight, selective thrombin inhibitor, inogatran, vs heparin, in unstable coronary artery disease in 1209 patients. A double-blind, randomized, dose-finding study. Thrombin inhibition in Myocardial Ischaemia (TRIM) study group (nl)
title	wds:Q74152408-ABB59634-A1A9-4B3B-9844-AFE7B20A1424
title	A low molecular weight, selective thrombin inhibitor, inogatran, vs heparin, in unstable coronary artery disease in 1209 patients. A double-blind, randomized, dose-finding study. Thrombin inhibition in Myocardial Ischaemia (TRIM) study group (en)
page(s)	wds:Q74152408-5A1DC35D-A5FD-4202-9A0C-67DED77BE000
page(s)	1416-1425
instance of	wds:Q74152408-EA8AEEF7-0594-4A1D-899F-592CF7C0E838
instance of	scholarly article
main subject	wds:Q74152408-9B0FD466-7E2B-4C06-BC19-50E8EE0997CC wds:Q74152408-A8D2F76B-B56B-4AFA-BF1B-6444C984821A
main subject	coronary artery disease heparin
PubMed ID	wds:Q74152408-FABF4FBA-8BE7-4241-9301-51FC4507BD17
PubMed ID	http://rdf.ncbi.nlm.nih.gov/pubchem/reference/9458447
PubMed ID	9458447
published in	wds:Q74152408-144E4ABF-2036-4283-BFFE-84294B583CC0
published in	European Heart Journal
issue	wds:Q74152408-F04B4D91-D670-44BD-9641-29BA0D0B573E
volume	wds:Q74152408-51CA1684-4AF9-4653-AE42-8114BCC80E3E
issue	9
volume	18
DOI	wds:Q74152408-1FB5B418-4B13-4D3A-94D7-5862CC0B943F
DOI	http://dx.doi.org/10.1093/OXFORDJOURNALS.EURHEARTJ.A015467
DOI	10.1093/OXFORDJOURNALS.EURHEARTJ.A015467
is about of	https://www.wikidata.org/wiki/Special:EntityData/Q74152408
is cites work of	Oral ximelagatran for secondary prophylaxis after myocardial infarction: the ESTEEM randomised controlled trial Direct thrombin inhibitors in acute coronary syndromes: principal results of a meta-analysis based on individual patients' data Reactivation of ischemic events in acute coronary syndromes: results from GUSTO-IIb. Gobal Use of Strategies To Open occluded arteries in acute coronary syndromes Low molecular weight heparins versus unfractionated heparin for acute coronary syndromes Synthetic inhibitors of thrombin and factor Xa: from bench to bedside Differences between local investigator and core laboratory interpretation of the admission electrocardiogram in patients with unstable angina pectoris or non-Q-wave myocardial infarction (a Thrombin Inhibition in Myocardial Ischemia [TRIM] substudy) Thrombolytic therapy: clinical applications Heparin is more effective than inogatran, a low-molecular weight thrombin inhibitor in suppressing ischemia and recurrent angina in unstable coronary disease. Thrombin Inhibition in Myocardial Ischemia (TRIM) Study Group. The pharmacodynamics and pharmacokinetics of the oral direct thrombin inhibitor ximelagatran and its active metabolite melagatran: a mini-review Thrombin inhibitors suppress the thrombin-thrombomodulin-mediated generation of activated protein C The evolving role of direct thrombin inhibitors in acute coronary syndromes Safety profile and tolerability of intravenous AR-C69931MX, a new antiplatelet drug, in unstable angina pectoris and non-Q-wave myocardial infarction Direct thrombin inhibitors in acute coronary syndromes Population modelling of the effect of inogatran, at thrombin inhibitor, on ex vivo coagulation time (APTT) in healthy subjects and patients with coronary artery disease Can we differentiate the low-molecular-weight heparins? Long term risk stratification of patients with acute coronary syndromes: characteristics of troponin T testing and continuous ST segment monitoring Comparative effects of unfractionated heparin and low molecular weight heparin on vascular endothelial cell tissue factor pathway inhibitor release: a model for assessing intrinsic thromboresistance New antithrombotic agents Admission risk assessment by cardiac troponin T in unstable coronary artery disease: additional prognostic information from continuous ST segment monitoring. TRIM study group. Thrombin Inhibition in Myocardial Ischemia Long-term management--the way forward? Relative contributions of a single-admission 12-lead electrocardiogram and early 24-hour continuous electrocardiographic monitoring for early risk stratification in patients with unstable coronary artery disease Admission standard electrocardiogram for early risk stratification in patients with unstable coronary artery disease not eligible for acute revascularization therapy: a TRIM substudy. ThRombin Inhibition in Myocardial Infarction Clinical significance of abnormal T waves in patients with non-ST-segment elevation acute coronary syndromes Introduction: Expanding the horizons in unstable coronary artery disease [Direct thrombin inhibitors: their role in the treatment of arterial and venous thrombosis] [New anthithrombotic drugs] Melagatran attenuates fibrin and platelet deposition in a porcine coronary aartery over-stretch injury model A critical review of clinical trials for low-molecular-weight heparin therapy in unstable coronary artery disease Management of patients with acute coronary syndromes: what is the clinical role of direct thrombin inhibitors? Proximal deep venous thrombosis occurring after sudden clopidogrel suspension. The influence of direct and antithrombin-dependent thrombin inhibitors on the procoagulant and anticoagulant effects of thrombin
is cites work of	wds:Q35081866-A1A64410-C4A6-4CB9-8E54-B44219F47E23 wds:Q78035754-5D7B6F5B-18CD-40FF-8CD2-F3C85DB35873 wds:Q33841036-3CCC5DC9-43C2-4C04-B7DB-38EAEE8EB6D0 wds:Q28193251-5525ACBA-08D9-47D0-A0F9-B3A71607408B wds:Q33540693-3530EAE3-55BC-474F-9C52-C5AC3F5DF117 wds:Q47290073-02CA61B0-BA9A-4A5B-AB07-C48CBBC82A07 wds:Q73459961-C2774AD1-C173-4678-8FF7-A584B38D364F wds:Q78679218-9EE8865E-3473-4BF6-AE73-8ECBA10935DD wds:Q34820259-BC246FAC-8B4D-4787-9109-A63707FD4EE4 wds:Q44777801-225B77F2-A891-4C1C-9F66-0122F863068E wds:Q40850697-46CF411B-61BF-44D3-BC48-7F435B9699F3 wds:Q24250287-59373751-D607-4DFB-B4D5-89684D5B2573 wds:Q73446080-7106ECCB-9BA2-4A53-A10F-DC236F7A457C wds:Q30671597-99C7A804-E4E0-4880-ACA5-2B8B559352F3 wds:Q35582508-817CFC7E-FAE0-49E6-A5B6-72BB98D3CA04 wds:Q42645616-70410BBF-11BB-40B3-964C-CA76984E8739 wds:Q77397128-6148583E-142F-4209-B672-20288D6E9F8E wds:Q28165358-BB08673D-1F38-4619-AB07-9093BAA7C9FD wds:Q28186283-D74EB569-DD9A-45A8-85A1-39FC14A29D05 wds:Q35159124-156CE590-2BBB-421F-9D40-72A9BE0A69F0 wds:Q35088077-084553F1-80EF-4534-92AA-4263BD112422 wds:Q77766241-31165A87-57AD-4C55-81CD-6375C6611E9B wds:Q77307393-CD749D68-145A-4E5F-84A2-D361A58C38D3 wds:Q28346958-9AB3DAF8-FB0D-438B-AD04-7670FB225975 wds:Q33841025-5537AF06-A753-4237-8576-B6C0C021E8E5 wds:Q44145222-EC14B4F9-E2B3-4488-988A-619A19642B6F wds:Q44403813-DF4F3F9F-4C3C-4E6A-9D0B-44788DA03F77 wds:Q44597996-8F524E9F-1624-422C-976A-1671A16DBB30 wds:Q44417488-778344F3-2B11-45B1-8DD0-3CD8724066AB wds:Q74611440-EB7E6D4B-63D1-452B-9CC4-81354E836CE3 wds:Q77761544-07176D46-F1CD-4E00-A2A3-FD6AF3FFDA54

Faceted Search & Find service v1.16.117 as of May 05 2024

Alternative Linked Data Documents: ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3239 as of May 5 2024, on Linux (x86_64-centos_6-linux-gnu), Single-Server Edition (378 GB total memory, 196 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software